RESUMEN
Herpes simplex virus (HSV) infections in allogeneic haematopoietic stem cell transplantation (HSCT) recipients pose significant challenges, with higher incidence, severity, and risk of emergence of resistance to antivirals due to impaired T-cell mediated immunity. This literature review focuses on acyclovir-refractory/resistant HSV infections in HSCT recipients. The review addresses the efficacy of antiviral prophylaxis, the incidence of acyclovir-refractory/resistant HSV infections, and the identification of risk factors and potential prognostic impact associated with those infections. Additionally, alternative therapeutic options are discussed. While acyclovir prophylaxis demonstrates a significant benefit in reducing HSV infections in HSCT recipients and, in some cases, overall mortality, concerns arise about the emergence of drug-resistant HSV strains. Our systematic review reports a median incidence of acyclovir-resistant HSV infections of 16.1%, with an increasing trend in recent years. Despite limitations in available studies, potential risk factors of emergence of HSV resistance to acyclovir include human leucocyte antigen (HLA) mismatches, myeloid neoplasms and acute leukaemias, and graft-versus-host disease (GVHD). Limited evidences suggest a potentially poorer prognosis for allogeneic HSCT recipients with acyclovir-refractory/resistant HSV infection. Alternative therapeutic approaches, such as foscarnet, cidofovir, topical cidofovir, optimised acyclovir dosing, and helicase-primase inhibitors offer promising options but require further investigations. Overall, larger studies are needed to refine preventive and therapeutic strategies for acyclovir-refractory/resistant HSV infections in allogeneic HSCT recipients and to identify those at higher risk.
Asunto(s)
Aciclovir , Antivirales , Farmacorresistencia Viral , Trasplante de Células Madre Hematopoyéticas , Herpes Simple , Humanos , Trasplante de Células Madre Hematopoyéticas/efectos adversos , Herpes Simple/tratamiento farmacológico , Herpes Simple/virología , Herpes Simple/terapia , Antivirales/uso terapéutico , Aciclovir/uso terapéutico , Simplexvirus/efectos de los fármacos , Simplexvirus/fisiología , Factores de Riesgo , Receptores de Trasplantes , IncidenciaRESUMEN
Herpes simplex virus (HSV) infections are highly widespread among humans, producing symptoms ranging from ulcerative lesions to severe diseases such as blindness and life-threatening encephalitis. At present, there are no vaccines available, and some existing antiviral treatments can be ineffective or lead to adverse effects. As a result, there is a need for new anti-HSV drugs. In this report, the in vitro anti-HSV effect of 9,9'-norharmane dimer (nHo-dimer), which belongs to the ß-carboline (ßC) alkaloid family, was evaluated. The dimer exhibited no virucidal properties and did not impede either the attachment or penetration steps of viral particles. The antiviral effect was only exerted under the constant presence of the dimer in the incubation media, and the mechanism of action was found to involve later events of virus infection. Analysis of fluorescence lifetime imaging data showed that the nHo-dimer internalized well into the cells when present in the extracellular incubation medium, with a preferential accumulation into perinuclear organelles including mitochondria. After washing the host cells with fresh medium free of nHo-dimer, the signal decreased, suggesting the partial release of the compound from the cells. This agrees with the observation that the antiviral effect is solely manifested when the alkaloid is consistently present in the incubation media.
Asunto(s)
Antivirales , Antivirales/farmacología , Antivirales/química , Chlorocebus aethiops , Humanos , Células Vero , Animales , Simplexvirus/efectos de los fármacos , Simplexvirus/fisiología , Herpes Simple/tratamiento farmacológico , Herpes Simple/virología , Carbolinas/farmacología , Carbolinas/química , Herpesvirus Humano 1/efectos de los fármacos , Herpesvirus Humano 1/fisiología , Harmina/farmacología , Harmina/química , Harmina/análogos & derivadosAsunto(s)
Aciclovir , Antivirales , Farmacorresistencia Viral , Trasplante de Células Madre Hematopoyéticas , Herpes Simple , Humanos , Aciclovir/uso terapéutico , Antivirales/uso terapéutico , Trasplante de Células Madre Hematopoyéticas/efectos adversos , Herpes Simple/tratamiento farmacológico , Herpes Simple/virología , Simplexvirus/efectos de los fármacos , Receptores de Trasplantes , Trasplante Homólogo/efectos adversos , Resultado del TratamientoRESUMEN
Herpetic gingivostomatitis and anogenital herpes are widely known manifestations of sexually transmitted herpesvirus infections. What is less recognized is the potential causative role of such infections in triggering immune-mediated skin disorders such as guttate psoriasis. We describe the case of a 23-year-old man with an acute episode of guttate psoriasis related to primary herpetic gingivostomatitis. The diagnosis of guttate psoriasis was pathologically confirmed and the condition fully regressed after proper antiviral therapy. This case adds herpes simplex virus to the growing list of pathogens capable of acting as triggers for guttate psoriasis and highlights the need for better insight of the relationship between psoriasis and viral infections.
Asunto(s)
Antivirales , Psoriasis , Estomatitis Herpética , Humanos , Masculino , Psoriasis/tratamiento farmacológico , Psoriasis/complicaciones , Estomatitis Herpética/tratamiento farmacológico , Estomatitis Herpética/diagnóstico , Adulto Joven , Antivirales/uso terapéutico , Resultado del Tratamiento , Simplexvirus/aislamiento & purificación , Simplexvirus/efectos de los fármacos , Herpes Simple/tratamiento farmacológico , Herpes Simple/diagnóstico , Herpes Simple/complicaciones , AdultoAsunto(s)
Aciclovir , Trasplante de Células Madre Hematopoyéticas , Herpes Simple , Simplexvirus , Activación Viral , Humanos , Trasplante de Células Madre Hematopoyéticas/efectos adversos , Aciclovir/uso terapéutico , Aciclovir/administración & dosificación , Activación Viral/efectos de los fármacos , Masculino , Femenino , Simplexvirus/efectos de los fármacos , Persona de Mediana Edad , Adulto , Antivirales/uso terapéutico , Antivirales/administración & dosificaciónRESUMEN
OBJECTIVE: JieZe-1 (JZ-1), a Chinese herbal prescription, has an obvious effect on genital herpes, which is mainly caused by herpes simplex virus type 2 (HSV-2). Our study aimed to address whether HSV-2 induces pyroptosis of VK2/E6E7 cells and to investigate the anti-HSV-2 activity of JZ-1 and the effect of JZ-1 on caspase-1-dependent pyroptosis. METHODS: HSV-2-infected VK2/E6E7 cells and culture supernate were harvested at different time points after the infection. Cells were co-treated with HSV-2 and penciclovir (0.078125 mg/mL) or caspase-1 inhibitor VX-765 (24 h pretreatment with 100 µmol/L) or JZ-1 (0.078125-50 mg/mL). Cell counting kit-8 assay and viral load analysis were used to evaluate the antiviral activity of JZ-1. Inflammasome activation and pyroptosis of VK2/E6E7 cells were analyzed using microscopy, Hoechst 33342/propidium iodide staining, lactate dehydrogenase release assay, gene and protein expression, co-immunoprecipitation, immunofluorescence, and enzyme-linked immunosorbent assay. RESULTS: HSV-2 induced pyroptosis of VK2/E6E7 cells, with the most significant increase observed 24 h after the infection. JZ-1 effectively inhibited HSV-2 (the 50% inhibitory concentration = 1.709 mg/mL), with the 6.25 mg/mL dose showing the highest efficacy (95.76%). JZ-1 (6.25 mg/mL) suppressed pyroptosis of VK2/E6E7 cells. It downregulated the inflammasome activation and pyroptosis via inhibiting the expression of nucleotide-binding oligomerization domain-like receptor family pyrin domain-containing protein 3 (P < 0.001) and interferon-γ-inducible protein 16 (P < 0.001), and their interactions with apoptosis-associated speck-like protein containing a caspase recruitment domain, and reducing cleaved caspase-1 p20 (P < 0.01), gasdermin D-N (P < 0.01), interleukin (IL)-1ß (P < 0.001), and IL-18 levels (P < 0.001). CONCLUSION: JZ-1 exerts an excellent anti-HSV-2 effect in VK2/E6E7 cells, and it inhibits caspase-1-dependent pyroptosis induced by HSV-2 infection. These data enrich our understanding of the pathologic basis of HSV-2 infection and provide experimental evidence for the anti-HSV-2 activity of JZ-1. Please cite this article as: Liu T, Shao QQ, Wang WJ, Liu TL, Jin XM, Xu LJ, Huang GY, Chen Z. The Chinese herbal prescription JieZe-1 inhibits caspase-1-dependent pyroptosis induced by herpes simplex virus-2 infection in vitro. J Integr Med. 2023; 21(3): 277-288.
Asunto(s)
Medicamentos Herbarios Chinos , Herpes Simple , Inflamasomas , Caspasa 1/metabolismo , Inflamasomas/metabolismo , Inflamasomas/farmacología , Proteína con Dominio Pirina 3 de la Familia NLR/metabolismo , Piroptosis , Simplexvirus/efectos de los fármacos , Simplexvirus/metabolismo , Medicamentos Herbarios Chinos/farmacología , Herpes Simple/tratamiento farmacológico , HumanosRESUMEN
ETHNOPHARMACOLOGICAL RELEVANCE: Apitherapy is a branch of traditional medicine that uses bee products to manage numerous diseases. In this context, the antiherpetic effect of these bee products has been demonstrated in some studies with some controversial results. AIM OF THE STUDY: Thus, we conducted a systematic review and meta-analysis to compare the effectiveness of honey and propolis with acyclovir, the reference drug, in the treatment of cold sores and genital herpes. MATERIALS AND METHODS: The selection of eligible studies was conducted through the search in Pubmed/MEDLINE, Scopus, Cochrane Library, LILACS, and Electronic Scientific Library. RESULTS: The search yielded 147 articles, of which nine were considered eligible for analysis. The analysis of these studies showed that the healing property of propolis is superior to that obtained for acyclovir (95% CI: 2.70 to 8.25; p = 0.0001). Furthermore, honey also presented a better healing effect than acyclovir against Herpes simplex virus-induced wounds (95% CI: 3.58 to -0.19; p = 0.03), inducing complete re-epithelization of herpetic lesions after 8 days, while for acyclovir, the healing time average was 9 days. It also provoked a similar reduction of pain caused by herpetic compared to acyclovir (95% CI: 2.27 to -0.42; p = 0.18). CONCLUSIONS: Overall, these results confirm the use of honey and propolis as potent antiherpetic agents.
Asunto(s)
Miel , Própolis/farmacología , Simplexvirus/efectos de los fármacos , Aciclovir/farmacología , Antivirales/farmacología , Herpes Simple/tratamiento farmacológico , Herpes Simple/virología , HumanosRESUMEN
Viral infections are among the most complex medical problems and have been a major threat to the economy and global health. Several epidemics and pandemics have occurred due to viruses, which has led to a significant increase in mortality and morbidity rates. Natural products have always been an inspiration and source for new drug development because of their various uses. Among all-natural sources, plant sources are the most dominant for the discovery of new therapeutic agents due to their chemical and structural diversity. Despite the traditional use and potential source for drug development, natural products have gained little attention from large pharmaceutical industries. Several plant extracts and isolated compounds have been extensively studied and explored for antiviral properties against different strains of viruses. In this review, we have compiled antiviral plant extracts and natural products isolated from plants reported since 2015.
Asunto(s)
Antivirales/aislamiento & purificación , Antivirales/farmacología , Productos Biológicos/farmacología , Desarrollo de Medicamentos , Extractos Vegetales/farmacología , Animales , Fármacos Anti-VIH/química , Fármacos Anti-VIH/aislamiento & purificación , Fármacos Anti-VIH/farmacología , Antivirales/química , Productos Biológicos/química , Productos Biológicos/aislamiento & purificación , Descubrimiento de Drogas , Flavivirus/efectos de los fármacos , Virus de Hepatitis/efectos de los fármacos , Humanos , Estructura Molecular , Orthomyxoviridae/efectos de los fármacos , Extractos Vegetales/química , Simplexvirus/efectos de los fármacosRESUMEN
Current therapy against herpes simplex viruses (HSV) relies on the use of a few nucleoside antivirals such as acyclovir, famciclovir and valacyclovir. However, the current drugs are ineffective against latent and drug-resistant HSV infections. A series of amidinourea compounds, designed as analogues of the antiviral drug moroxydine, has been synthesized and evaluated as potential non-nucleoside anti-HSV agents. Three compounds showed micromolar activity against HSV-1 and low cytotoxicity, turning to be promising candidates for future optimization. Preliminary mode of action studies revealed that the new compounds act in an early stage of the HSV replication cycle, just after the viral attachment and the entry phase of the infection.
Asunto(s)
Guanidina/análogos & derivados , Herpes Simple/tratamiento farmacológico , Herpesvirus Humano 1/efectos de los fármacos , Simplexvirus/efectos de los fármacos , Urea/análogos & derivados , Aciclovir/efectos adversos , Aciclovir/farmacología , Antivirales/farmacología , Farmacorresistencia Viral/genética , Guanidina/síntesis química , Guanidina/farmacología , Herpes Simple/virología , Herpesvirus Humano 1/patogenicidad , Humanos , Simplexvirus/genética , Simplexvirus/patogenicidad , Urea/síntesis química , Urea/farmacologíaRESUMEN
Herpes simplex viruses (HSV) are ubiquitously distributed with a seroprevalence ranging up to 95% in the adult population. Refractory viral infections with herpes simplex virus type 1 (HSV-1) and type 2 (HSV-2) represent a major global health issue. In particular, the increasing occurrence of resistance to conventional antiviral drugs make the therapy of such infections even more challenging. For instance, the frequent and long-term use of acyclovir and other nucleoside analogues targeting the viral DNA-polymerase enhance the development of resistant viruses. Particularly, the incidental increase of those strains in immunocompromised patients is alarming and represent a major health concern. Alternative treatment concepts are clearly needed. Natural products such as herbal medicines showed antiherpetic activity in vitro and in vivo and proved to be an excellent source for the discovery and isolation of novel antivirals. By this means, numerous plant-derived compounds with antiviral or antimicrobial activity could be isolated. Natural medicines and their ingredients are well-tolerated and could be a good alternative for treating herpes simplex virus infections. This review provides an overview of the recent status of natural sources such as plants, bacteria, fungi, and their ingredients with antiviral activity against herpes simplex viruses. Furthermore, we highlight the most potent herbal medicines and ingredients as promising candidates for clinical investigation and give an overview about the most important drug classes along with their potential antiviral mechanisms. The content of this review is based on articles that were published between 1996 and 2021.
Asunto(s)
Antivirales/química , Antivirales/farmacología , Productos Biológicos/farmacología , Simplexvirus/efectos de los fármacos , Animales , Antivirales/uso terapéutico , Productos Biológicos/química , Productos Biológicos/uso terapéutico , Ensayos Clínicos como Asunto , Herpes Simple/tratamiento farmacológico , Herpes Simple/virología , Humanos , Ratones , Extractos Vegetales/química , Extractos Vegetales/farmacología , Plantas Medicinales/química , Simplexvirus/clasificaciónRESUMEN
BACKGROUND: Although oncolytic virotherapy has shown substantial promises as a new treatment modality for many malignancies, further improvement on its therapeutic efficacy will likely bring more clinical benefits. One plausible way of enhancing the therapeutic effect of virotherapy is to enable it with the ability to concurrently engage the infiltrating immune cells to provide additional antitumor mechanisms. Here, we report the construction and evaluation of two novel chimeric molecules (bispecific chimeric engager proteins, BiCEP and trispecific chimeric engager protein, TriCEP) that can engage both natural killer (NK) and T cells with tumor cells for enhanced antitumor activities. METHODS: BiCEP was constructed by linking orthopoxvirus major histocompatibility complex class I-like protein, which can selectively bind to NKG2D with a high affinity to a mutant form of epidermal growth factor (EGF) that can strongly bind to EGF receptor. TriCEP is similarly constructed except that it also contains a modified form of interleukin-2 that can only function as a tethered form. As NKG2D is expressed on both NK and CD8+ T cells, both of which can thus be engaged by BiCEP and TriCEP. RESULTS: Both BiCEP and TriCEP showed the ability to engage NK and T cells to kill tumor cells in vitro. Coadministration of BiCEP and TriCEP with an oncolytic herpes simplex virus enhanced the overall antitumor effect. Furthermore, single-cell RNA sequencing analysis revealed that TriCEP not only engaged NK and T cells to kill tumor cells, it also promotes the infiltration and activation of these important immune cells. CONCLUSIONS: These novel chimeric molecules exploit the ability of the oncolytic virotherapy in altering the tumor microenvironment with increased infiltration of important immune cells such as NK and T cells for cancer immunotherapy. The ability of BiCEP and TriCEP to engage both NK and T cells makes them an ideal choice for arming an oncolytic virotherapy.
Asunto(s)
Anticuerpos Biespecíficos/metabolismo , Viroterapia Oncolítica/métodos , Virus Oncolíticos/genética , Simplexvirus/efectos de los fármacos , Humanos , Simplexvirus/genéticaRESUMEN
Herpes simplex virus is among the most prevalent sexually transmitted infections. Acyclovir is a potent, selective inhibitor of herpes viruses and it is indicated for the treatment and management of recurrent cold sores on the lips and face, genital herpes, among other diseases. The problem of the oral bioavailability of acyclovir is limited because of the low permeability across the gastrointestinal membrane. The use of nanoparticles of pseudoboehmite as a drug delivery system in vitro assays is a promising approach to further the permeability of acyclovir release. Here we report the synthesis of high purity pseudoboehmite from aluminium nitrate and ammonium hydroxide containing nanoparticles, using the sol-gel method, as a drug delivery system to improve the systemic bioavailability of acyclovir. The presence of pseudoboehmite nanoparticles were verified by infrared spectroscopy, transmission electron microscopy, and X-ray diffraction techniques. In vivo tests were performed with Wistar rats to compare the release of acyclovir, with and without the addition of pseudoboehmite. The administration of acyclovir with the addition of pseudoboehmite increased the drug content by 4.6 times in the plasma of Wistar rats after 4 h administration. We determined that the toxicity of pseudoboehmite is low up to 10 mg/mL, in gel and the dried pseudoboehmite nanoparticles.
Asunto(s)
Aciclovir/administración & dosificación , Hidróxido de Aluminio/química , Óxido de Aluminio/química , Antivirales/administración & dosificación , Sistemas de Liberación de Medicamentos/métodos , Nanogeles/química , Aciclovir/sangre , Aciclovir/farmacocinética , Administración Oral , Hidróxido de Aluminio/farmacología , Óxido de Aluminio/farmacología , Animales , Antivirales/sangre , Antivirales/farmacocinética , Disponibilidad Biológica , Células CACO-2 , Supervivencia Celular/efectos de los fármacos , Liberación de Fármacos , Herpes Simple/tratamiento farmacológico , Herpes Simple/virología , Humanos , Modelos Animales , Ratas , Ratas Wistar , Simplexvirus/efectos de los fármacosRESUMEN
Global processes, such as climate change, frequent and distant travelling and population growth, increase the risk of viral infection spread. Unfortunately, the number of effective and accessible medicines for the prevention and treatment of these infections is limited. Therefore, in recent years, efforts have been intensified to develop new antiviral medicines or vaccines. In this review article, the structure and activity of the most promising antiviral cyanobacterial products are presented. The antiviral cyanometabolites are mainly active against the human immunodeficiency virus (HIV) and other enveloped viruses such as herpes simplex virus (HSV), Ebola or the influenza viruses. The majority of the metabolites are classified as lectins, monomeric or dimeric proteins with unique amino acid sequences. They all show activity at the nanomolar range but differ in carbohydrate specificity and recognize a different epitope on high mannose oligosaccharides. The cyanobacterial lectins include cyanovirin-N (CV-N), scytovirin (SVN), microvirin (MVN), Microcystisviridis lectin (MVL), and Oscillatoria agardhii agglutinin (OAA). Cyanobacterial polysaccharides, peptides, and other metabolites also have potential to be used as antiviral drugs. The sulfated polysaccharide, calcium spirulan (CA-SP), inhibited infection by enveloped viruses, stimulated the immune system's response, and showed antitumor activity. Microginins, the linear peptides, inhibit angiotensin-converting enzyme (ACE), therefore, their use in the treatment of COVID-19 patients with injury of the ACE2 expressing organs is considered. In addition, many cyanobacterial extracts were revealed to have antiviral activities, but the active agents have not been identified. This fact provides a good basis for further studies on the therapeutic potential of these microorganisms.
Asunto(s)
Antivirales/química , Cianobacterias/química , VIH/efectos de los fármacos , Lectinas/farmacología , Polisacáridos/farmacología , SARS-CoV-2/efectos de los fármacos , Simplexvirus/efectos de los fármacos , Fármacos Anti-VIH/farmacología , Antineoplásicos/farmacología , Antivirales/farmacología , Proteínas Bacterianas/química , Proteínas Bacterianas/farmacología , Carbohidratos/química , Carbohidratos/farmacología , Cianobacterias/metabolismo , Infecciones por VIH/tratamiento farmacológico , Humanos , Lectinas/química , Lectinas/metabolismo , Polisacáridos/química , Polisacáridos/metabolismo , Tratamiento Farmacológico de COVID-19RESUMEN
Limited options for the treatments of diseases triggered through viral infections revealed the quest for novel antiviral drugs. Polysaccharide sulfates owing to their unique mode of action are prominent antiviral drug candidates. Herein, the arabinoxylan of Plantago ovata seed husk was simultaneously extracted and chemically sulfated using sulphur trioxide-pyridine reagent in N,N-dimethylformamide solvent (SO3â Py/DMF). Thus, three arabinoxylan sulfates (IS1201-IS1203) holding variable degrees of sulfation (DS: 0.1-0.9), molar masses (18.4-31.3 kDa) and glycosyl makeup (Ara: Xyl::10-19:81-90; molar ratio) were produced and then characterized. According to the results, these polymers displayed anti-herpes simplex virus type 1 activity and their potency depends upon DS. The utmost effective compound (IS1203, IC50: 2.9 µg mL-1) was a 18.4 kDa arabinoxylan possessing sulfate groups at O-3 and O-2,3 positions of xylopyranosyl (Xylp), and O-5 of arabinofuranosyl (Araf) residues. Besides, this polymer showed no cytotoxicity at concentration up to 1000 µg mL-1. Given that polysaccharide sulfates have antiviral activities, synthesis of new molecules possessing diverse structures will be a useful addition to the arsenal of antivirals.
Asunto(s)
Antivirales/farmacología , Plantago/química , Polisacáridos/química , Sulfatos/química , Xilanos/química , Animales , Chlorocebus aethiops , Glicósidos/química , Concentración 50 Inhibidora , Metilación , Peso Molecular , Polímeros/química , Semillas/química , Simplexvirus/efectos de los fármacos , Espectrofotometría Infrarroja , Espectrofotometría Ultravioleta , Relación Estructura-Actividad , Células VeroRESUMEN
Herpes simplex virus one is one of the most prevalent pathogens worldwide. Strains resistant to current treatment have been reported, so it is necessary to search for new antiviral molecules. The most common method to quantify antiviral activity from natural products is the plaque reduction assay, a technically demanding method. In order to provide a simple alternative to this method, we have established a procedure for viral quantification by qPCR, and coupled with a cytotoxicity evaluation system using resazurin. In this way, it is possible to obtain both the estimation of cytotoxicity and the antiviral activity simultaneously, allowing rapid screening of plant extracts. Ten out of twenty-eight Paraguayan medicinal plant extracts evaluated using this method showed antiviral activity, and the EC50, CC50, and SI values were calculated for each extract. Our experience supports the employment of the described method for a rapid identification of plant extracts with antiviral activity.
Asunto(s)
Antivirales/farmacología , Plantas Medicinales , Simplexvirus/efectos de los fármacos , Animales , Antivirales/aislamiento & purificación , Chlorocebus aethiops , Herpes Simple/tratamiento farmacológico , Paraguay , Fitoquímicos/aislamiento & purificación , Fitoquímicos/farmacología , Extractos Vegetales/farmacología , Plantas Medicinales/química , Reacción en Cadena en Tiempo Real de la Polimerasa , Células VeroRESUMEN
Corneal infections by viruses and bacteria can result in ocular surface defects, ulcers, or wounds. Herpes simplex virus type-1 (HSV-1) is a human virus with global seroprevalence in the range of 60-90%. While the virus more commonly causes mucocutaneous lesions including ulcers on the face and mouth, it is also a leading cause of infection-associated blindness. In this chapter, we discuss an in-depth protocol required to evaluate corneal damage due to HSV-1 infection using porcine models of ex vivo infection. Our methods can be adapted to study similar infections caused by other viruses and bacteria.
Asunto(s)
Lesiones de la Cornea/virología , Modelos Animales de Enfermedad , Queratitis Herpética/virología , Simplexvirus/fisiología , Técnicas de Cultivo de Tejidos/métodos , Animales , Antivirales/farmacología , Chlorocebus aethiops , Córnea/citología , Córnea/virología , Lesiones de la Cornea/etiología , Lesiones de la Cornea/patología , Interacciones Huésped-Patógeno , Queratitis Herpética/patología , Simplexvirus/efectos de los fármacos , Simplexvirus/patogenicidad , Porcinos , Células Vero , Internalización del Virus , Replicación Viral/efectos de los fármacosRESUMEN
Recurrent infections with herpes simplex virus (HSV) in the orofacial (cold sores), ocular or genital region are common and sometimes disabling, calling for an effective preventive intervention. The bacillus Calmette-Guérin (BCG) vaccine has beneficial off-target effects that might impact recurrence of HSV infections. In this systematic review, Medline, EMBASE, and PubMed were searched in June 2020; 16 articles were deemed relevant comprising eight animal and eight human studies (301 patients). In animals, BCG administration led to a 1.9 to 5.5-fold increase in survival rate following HSV challenge (vaginal, corneal, or intraperitoneal inoculation). This beneficial effect was influenced by the dose of BCG (higher better), mode of administration (intradermal better than intraperitoneal), and the interval between vaccination and viral challenge (at least 6 days required). In nonrandomized human studies (that failed to control for a placebo effect), BCG vaccination appeared beneficial in 78% of adults with recurrent herpes genitalis or labialis, with 37% being recurrence-free for an extended period, 41% experiencing less frequent or severe episodes, and only 22% reporting no change. This clinical benefit is consistent with the findings of immunological sub-studies. In the two studies restricted to recurrent herpes labialis, 94% appeared to benefit from BCG. The one randomized controlled trial used an intervention in the control group that has immunomodulatory effects thus limiting interpretation. In conclusion, BCG vaccine is a potential, safe, affordable and readily available candidate intervention to decrease the high burden of disease associated with HSV infection and recurrences, but properly controlled randomized trials are required.
Asunto(s)
Vacuna BCG/farmacología , Herpes Simple/prevención & control , Prevención Secundaria , Simplexvirus/efectos de los fármacos , Herpes Genital , Humanos , Recurrencia , Simplexvirus/patogenicidadRESUMEN
Upon sensing cytosolic DNA, the enzyme cGAS induces innate immune responses that underpin anti-microbial defenses and certain autoimmune diseases. Missense mutations of PRKDC encoding the DNA-dependent protein kinase (DNA-PK) catalytic subunit (DNA-PKcs) are associated with autoimmune diseases, yet how DNA-PK deficiency leads to increased immune responses remains poorly understood. In this study, we report that DNA-PK phosphorylates cGAS and suppresses its enzymatic activity. DNA-PK deficiency reduces cGAS phosphorylation and promotes antiviral innate immune responses, thereby potently restricting viral replication. Moreover, cells isolated from DNA-PKcs-deficient mice or patients carrying PRKDC missense mutations exhibit an inflammatory gene expression signature. This study provides a rational explanation for the autoimmunity of patients with missense mutations of PRKDC, and suggests that cGAS-mediated immune signaling is a potential target for therapeutic interventions.
Asunto(s)
Antivirales/metabolismo , Proteína Quinasa Activada por ADN/deficiencia , Inmunidad Innata , Nucleotidiltransferasas/metabolismo , Animales , Línea Celular , Cromonas/farmacología , Proteína Quinasa Activada por ADN/antagonistas & inhibidores , Proteína Quinasa Activada por ADN/metabolismo , Femenino , Fibroblastos/efectos de los fármacos , Fibroblastos/metabolismo , Humanos , Masculino , Ratones Endogámicos C57BL , Morfolinas/farmacología , Fosforilación/efectos de los fármacos , Inhibidores de Proteínas Quinasas/farmacología , Multimerización de Proteína/efectos de los fármacos , ARN Guía de Kinetoplastida/metabolismo , Transducción de Señal/efectos de los fármacos , Simplexvirus/efectos de los fármacos , Simplexvirus/fisiología , Células THP-1 , Vesiculovirus/efectos de los fármacos , Vesiculovirus/fisiología , Replicación Viral/efectos de los fármacosRESUMEN
Curcumin is a natural compound that has many medical applications. However, its low solubility and poor stability could impede its clinical applications. The present study aimed to formulate dry proniosomes to overcome these pitfalls and improve the therapeutic efficacy of Curcumin. Curcumin-loaded proniosomes were fabricated by the slurry method according to 32 factorial design using Design-Expert software to demonstrate the impact of different independent variables on entrapment efficiency (EE%) and % drug released after 12 h (Q12h). The optimized formula (F5) was selected according to the desirability criteria. F5 exhibited good flowability and appeared, after reconstitution, as spherical nanovesicles with EE% of 89.94 ± 2.31% and Q12h of 70.89 ± 1.62%. F5 demonstrated higher stability and a significant enhancement of Q12h than the corresponding niosomes. The docking study investigated the ability of Curcumin to bind effectively with the active site of DNA polymerase of Herpes simplex virus (HSV). The antiviral activity and the safety of F5 were significantly higher than Curcumin. F5 improved the safety of Acyclovir (ACV) and reduced its effective dose that produced a 100% reduction of viral plaques. Proniosomes could be promising stable carriers of Curcumin to be used as a safe and efficient antiviral agent.